Dona 500mg Capsules
- Name:
Dona 500mg Capsules
- Company:
Mylan IRE Healthcare Limited
- Active Ingredients:
- Legal Category:
Supply through pharmacy only
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 15/08/18
(Click to Download)Click on this link to Download PDF directly
Mylan IRE Healthcare Limited
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 15 August 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 15 August 2018
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - Marketing authorisation number(s)
- Change to section 10 - Date of revision of the text
Updated on 8 May 2018
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Updated on 29 July 2016 PIL
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
In section 2: Very minor text change
In section 4.2: Minor text changes and method of administration added.
In section 4.3: Minor text addition.
In section 4.4: Information regarding the presence of other joint disease added.
In section 4.5: Information regarding steroidal or non-steroidal analgesic or anti-inflammatory agents added.
In section 4.7: Information regarding effects on the ability to drive added: no important effects on the CNS or motor system known.
In section 4.8: Addition of some undesirable effects and removal of some undesirable effects. Addition of adverse reaction reporting statement.
In section 4.9: Addition of information.
In section 5.1: Pharmacotherapeutic group added. Complete rewrite of section.
In section 5.2: Information added regarding absorption, distribution, metabolism, excretion and special populations.
In section 5.3: Complete rewrite of section
In section 10: Date of revision has changedUpdated on 29 July 2016 SPC
Reasons for updating
- Change to section 2 - Qualitative and quantitative composition
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to Section 4.8 – Undesirable effects - how to report a side effect
- Change to section 4.9 - Overdose
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 5.3 - Preclinical safety data
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
In section 2: Very minor text change
In section 4.2: Minor text changes and method of administration added.
In section 4.3: Minor text addition.
In section 4.4: Information regarding the presence of other joint disease added.
In section 4.5: Information regarding steroidal or non-steroidal analgesic or anti-inflammatory agents added.
In section 4.7: Information regarding effects on the ability to drive added: no important effects on the CNS or motor system known.
In section 4.8: Addition of some undesirable effects and removal of some undesirable effects. Addition of adverse reaction reporting statement.
In section 4.9: Addition of information.
In section 5.1: Pharmacotherapeutic group added. Complete rewrite of section.
In section 5.2: Information added regarding absorption, distribution, metabolism, excretion and special populations.
In section 5.3: Complete rewrite of section
In section 10: Date of revision has changedUpdated on 29 July 2016
Reasons for updating
- New SmPC for new product
Legal category: Supply through pharmacy only
Updated on 27 November 2015 PIL
Reasons for updating
- Change to section 10 - Date of revision of the text
Free text change information supplied by the pharmaceutical company
Updated on 27 November 2015 SPC
Reasons for updating
- Change to section 10 - Date of revision of the text
Legal category: Supply through pharmacy only
Free text change information supplied by the pharmaceutical company
Updated on 25 November 2015 PIL
Reasons for updating
- New SPC for medicines.ie
Free text change information supplied by the pharmaceutical company
Updated on 25 November 2015 SPC
Reasons for updating
- New SPC for medicines.ie
Legal category: Supply through pharmacy only